Log in to save to my catalogue

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clini...

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clini...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b4d656f611a1492fa65ae4695339c26b

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

About this item

Full title

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Publisher

England: EULAR

Journal title

Rheumatic & musculoskeletal diseases open, 2022-11, Vol.8 (2), p.e002560

Language

English

Formats

Publication information

Publisher

England: EULAR

More information

Scope and Contents

Contents

ObjectiveSuccessful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).MethodsObser...

Alternative Titles

Full title

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b4d656f611a1492fa65ae4695339c26b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b4d656f611a1492fa65ae4695339c26b

Other Identifiers

ISSN

2056-5933

E-ISSN

2056-5933

DOI

10.1136/rmdopen-2022-002560

How to access this item